April 23, 2026
“Neurofeedback finally has a defensible target — the amygdala — and an FDA-cleared path to the clinic. The question is no longer whether it works, but for whom.”
“Cluster-C personality disorders cost €27K–€60K per patient per year and still do not get a fraction of the research attention we give BPD.”
“The clinical scale of the next decade is not a scale. It is the phone already in the patient's pocket.”
“In a decade, anxiety disorders among older adults in the US state system went from 13% to 23% — the caseload has changed more than the system has.”
“The question with digital therapeutics is not whether they work, but whether they move the market. Rejoyn's answer at 24 months: yes on regulatory plumbing, unfinished on clinical uptake.”
“The training that maps onto the next five years of trauma work — complex PTSD, somatic integration, psychedelic assisted — is IFS. In 2026 the door is open but narrow, and getting narrower.”